Jake Simson is a partner at RA Capital Management. Jake works on both public and private investments and serves as a board director for Xenikos, B.V., Tyra Biosciences and AavantiBio. Previously, Jake covered solid tumor oncology landscapes.
Jake holds a B.S. in materials science and engineering from MIT and a Ph.D. in biomedical engineering from Johns Hopkins University. In his doctoral research, he investigated clinically translatable treatments for musculoskeletal tissue repair using injectable hydrogels.